Video

Dr. Cervantes Discusses COMFORT-II Long-Term Data

Francisco Cervantes, MD, PhD, Hospital Clinic, IDIBAPS, Barcelona, Spain, discusses the initial and long-term findings of the COMFORT-II trial of ruxolitib for the treatment of myelofibrosis.

Francisco Cervantes, MD, PhD, Hospital Clinic, Institut d'investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain, discusses the initial and long-term findings of the COMFORT-II trial of ruxolitinib for the treatment of myelofibrosis.

Ruxolitinib is a JAK inhibitor that showed superiority in the phase III COMFORT-I and phase III COMFORT-II trials. In the COMFORT-I trial, ruxolitinib was compared to placebo for the treatment of myelofibrosis and showed superiority in reducing spleen volume, improving symptoms, and prolonging survival and quality of life. In the parallel COMFORT-II trial, patients received ruxolitinib or best available therapy (BAT). Ruxolitinib demonstrated superior spleen volume reduction as well as myelofibrosis-related symptom reduction.

In the long-term safety, efficacy, and survival findings from the COMFORT-II trial, which Cervantes presented at the 2012 American Society of Hematology Meeting, ruxolitinib showed maintained responses and survival benefit for more than two years. The follow-up data showed that 48.3% of ruxolitinib patients achieved a ≥ 35% reduction from baseline in spleen volume at any time during the study. Since the previous report, 14% of patients receiving ruxolitinib died compared to 22% of BAT patients.

Related Videos
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School